BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251-257. [PMID: 15290920 DOI: 10.1097/00054725-200405000-00012] [Cited by in Crossref: 97] [Cited by in F6Publishing: 91] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ishiguro Y, Ohmori T, Umemura K, Iizuka M. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study. Ther Apher Dial 2021;25:502-12. [PMID: 33029920 DOI: 10.1111/1744-9987.13594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. J Gastroenterol. 2020;55:390-400. [PMID: 31811562 DOI: 10.1007/s00535-019-01651-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
5 Naganuma M. Treatment with indigo naturalis for inflammatory bowel disease and other immune diseases. Immunol Med 2019;42:16-21. [PMID: 31034341 DOI: 10.1080/25785826.2019.1599158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
6 Ronchetti S, Ricci E, Migliorati G, Gentili M, Riccardi C. How Glucocorticoids Affect the Neutrophil Life. Int J Mol Sci. 2018;19. [PMID: 30563002 DOI: 10.3390/ijms19124090] [Cited by in Crossref: 44] [Cited by in F6Publishing: 67] [Article Influence: 11.0] [Reference Citation Analysis]
7 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Intern Med. 2017;56:2705-2710. [PMID: 28924114 DOI: 10.2169/internalmedicine.8428-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
8 Sagawa T, Kakizaki S, Tomizawa T, Nakayama T, Tanaka H, Tojima H, Sato K, Kusano M, Okamura S, Yamada M. Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy. Colorectal Dis 2016;18:696-702. [PMID: 26748553 DOI: 10.1111/codi.13258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
9 Rodríguez-lago I, Gómez-irwin L, Fernández E, Higuera R, Cabriada JL. Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis: Granulocyte-Monocyte Apheresis After Anti-TNF Failure. Ther Apher Dial 2017;21:26-30. [DOI: 10.1111/1744-9987.12485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Di Girolamo M, Sartini A, Critelli R, Bertani A, Merighi A, Villa E. Efficacy of a Novel Granulocyte Monocyte Apheresis Adsorber Device in the Treatment of Inflammatory Bowel Diseases: A Pilot Study. Ther Apher Dial 2016;20:668-76. [PMID: 27921374 DOI: 10.1111/1744-9987.12453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol 2016;9:329-36. [DOI: 10.1007/s12328-016-0686-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
12 Takayama T, Okamoto S, Hisamatsu T, Naganuma M, Matsuoka K, Mizuno S, Bessho R, Hibi T, Kanai T. Computer-Aided Prediction of Long-Term Prognosis of Patients with Ulcerative Colitis after Cytoapheresis Therapy. PLoS One 2015;10:e0131197. [PMID: 26111148 DOI: 10.1371/journal.pone.0131197] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
13 Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study. J Clin Apher. 2014;29:107-112. [PMID: 24000140 DOI: 10.1002/jca.21299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
14 Nakano R, Iwakiri R, Ikeda Y, Kishi T, Tsuruoka N, Shimoda R, Sakata Y, Yamaguchi K, Fujimoto K. Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. J Gastroenterol Hepatol 2013;28:303-8. [PMID: 23339387 DOI: 10.1111/jgh.12049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
15 Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis. 2013;7:e692-e697. [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
16 Toya Y, Chiba T, Mizutani T, Sato K, Kasugai S, Matsuda N, Orikasa S, Shibata S, Abiko Y, Akasaka R. The effect of granulocyte and monocyte adsorptive apheresis on serum cytokine levels in patients with ulcerative colitis. Cytokine. 2013;62:146-150. [PMID: 23465691 DOI: 10.1016/j.cyto.2013.01.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
17 Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
18 Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
19 Shiraki M, Yamamoto T. Steroid-sparing strategies in the management of ulcerative colitis: Efficacy of leukocytapheresis. World J Gastroenterol 2012; 18(41): 5833-5838 [PMID: 23139598 DOI: 10.3748/wjg.v18.i41.5833] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
20 Fukunaga K, Matsumoto T. Current status and future perspectives of leukocytapheresis for inflammatory bowel disease. J Gastroenterol Hepatol. 2012;27:997-1003. [PMID: 22414250 DOI: 10.1111/j.1440-1746.2012.07119.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
21 Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis. 2013;7:e49-e54. [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sakuraba A, Sato T, Morohoshi Y, Matsuoka K, Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. Intermittent granulocyte and monocyte apheresis versus mercaptopurine for maintaining remission of ulcerative colitis: a pilot study. Ther Apher Dial. 2012;16:213-218. [PMID: 22607563 DOI: 10.1111/j.1744-9987.2012.01064.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
24 Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol. 2012;47:49-55. [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
26 Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011;46:1003-9. [PMID: 21681409 DOI: 10.1007/s00535-011-0428-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
27 D'Ovidio V, Meo D, Viscido A, Bresci G, Vernia P, Caprilli R. Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. World J Gastroenterol 2011; 17(14): 1831-1835 [PMID: 21528055 DOI: 10.3748/wjg.v17.i14.1831] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
28 Sanchez-Garcia J, Serrano-López J, García-Sanchez V, Alvarez-Rivas MA, Jimenez-Moreno R, Pérez-Seoane C, Herrera-Arroyo C, Serrano J, de Dios JF, Torres-Gomez A. Tumor necrosis factor-α-secreting CD16+ antigen presenting cells are effectively removed by granulocytapheresis in ulcerative colitis patients. J Gastroenterol Hepatol 2010;25:1869-75. [PMID: 21091999 DOI: 10.1111/j.1440-1746.2010.06377.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16:1905-1911. [PMID: 20310015 DOI: 10.1002/ibd.21260] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
30 Ng SC, Chan FKL, Sung JJY. Review article: the role of non-biological drugs in refractory inflammatory bowel disease: Review: refractory inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2011;33:417-27. [DOI: 10.1111/j.1365-2036.2010.04541.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
31 Naganuma M, Fujii T, Watanabe M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol. 2011;46:129-137. [PMID: 21132334 DOI: 10.1007/s00535-010-0352-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
32 Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol. 2010;34:687-695. [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
33 Ooi CJ, Fock KM, Makharia GK, Goh KL, Ling KL, Hilmi I, Lim WC, Kelvin T, Gibson PR, Gearry RB. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453-468. [PMID: 20370724 DOI: 10.1111/j.1440-1746.2010.06241.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 112] [Article Influence: 8.1] [Reference Citation Analysis]
34 Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, Kanai T, Ogata H, Iwao Y, Hibi T. Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. J Gastroenterol 2010;45:936-43. [DOI: 10.1007/s00535-010-0244-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
35 Yamaguchi T, Yoshida S, Tanaka S, Takemura Y, Oka S, Yoshihara M, Yamada H, Chayama K. Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonography. Scand J Gastroenterol 2009;44:831-7. [PMID: 19811342 DOI: 10.1080/00365520902839659] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
36 Takeda S, Sato T, Katsuno T, Nakagawa T, Noguchi Y, Yokosuka O, Saito Y. Adsorptive depletion of alpha4 integrin(hi)- and CX3CR1hi-expressing proinflammatory monocytes in patients with ulcerative colitis. Dig Dis Sci. 2010;55:1886-1895. [PMID: 19908144 DOI: 10.1007/s10620-009-0974-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
37 Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis. 2010;42:432-435. [PMID: 19833566 DOI: 10.1016/j.dld.2009.09.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
38 Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Kawakami T, Yamazaki M, Soma Y. Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. Am J Gastroenterol 2009;104:2363-4. [PMID: 19727102 DOI: 10.1038/ajg.2009.271] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
40 Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990-2995. [PMID: 19724269 DOI: 10.1038/ajg.2009.453] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
41 Nos P, Domènech E. Tratamiento con aféresis en la enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 2009;32:509-18. [DOI: 10.1016/j.gastrohep.2009.01.183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
42 Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2009;15:935-950. [PMID: 18985710 DOI: 10.1002/ibd.20797] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
43 Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis. 2009;15:328-334. [PMID: 18942752 DOI: 10.1002/ibd.20759] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
44 Iwakami Y, Sakuraba A, Sato T, Takada Y, Izumiya M, Ichikawa H, Hibi T. Granulocyte and Monocyte Adsorption Apheresis Therapy Modulates Monocyte-Derived Dendritic Cell Function in Patients With Ulcerative Colitis: GMA Modulates moDC Function. Therapeutic Apheresis and Dialysis 2009;13:138-46. [DOI: 10.1111/j.1744-9987.2009.00668.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
45 Sakata Y, Iwakiri R, Amemori S, Yamaguchi K, Fujise T, Otani H, Shimoda R, Tsunada S, Sakata H, Ikeda Y, Ando T, Nakafusa Y, Fujimoto K. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur J Gastroenterol Hepatol 2008;20:629-33. [PMID: 18679064 DOI: 10.1097/MEG.0b013e3282f5e9a4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
46 Bresci G. Granulocytapheresis in the treatment of patients with active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2008;2:639-43. [PMID: 19072341 DOI: 10.1586/17474124.2.5.639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Ghosh S, Kaplan G, Panaccione R. Granulocyte–monocyte apheresis for the treatment of ulcerative colitis—is this the end of the road? Nat Rev Gastroenterol Hepatol 2009;6:6-7. [DOI: 10.1038/ncpgasthep1299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
48 Takeda H, Suzuki Y, Takeda Y, Nishise S, Fukui T, Fujishima S, Orii T, Otake S, Sato T, Suzuki K, Nakamuara Y, Kawata S. A multi center study of granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis-clinical efficacy and production of interleukin-1 receptor antagonist. J Clin Apher 2008;23:105-10. [PMID: 18449931 DOI: 10.1002/jca.20164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
49 Umehara Y, Kudo M, Kawasaki M. Endoscopic findings can predict the efficacy of leukocytapheresis for steroid-naive patients with moderately active ulcerative colitis. World J Gastroenterol 2008; 14(34): 5316-5321 [PMID: 18785285 DOI: 10.3748/wjg.14.5316] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
50 Sigurbjörnsson FT, Bjarnason I. Leukocytapheresis for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2008;5:509-516. [PMID: 18665138 DOI: 10.1038/ncpgasthep1209] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
51 Martín de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr. 2008;46:386-391. [PMID: 18367949 DOI: 10.1097/mpg.0b013e31815604e5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
52 Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400-409. [PMID: 18602921 DOI: 10.1053/j.gastro.2008.04.023] [Cited by in Crossref: 150] [Cited by in F6Publishing: 150] [Article Influence: 10.7] [Reference Citation Analysis]
53 Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008;40:731-6. [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
54 Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 2008;77:96-107. [PMID: 18382085 DOI: 10.1159/000122473] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
55 Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis. 2008;40:433-440. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
56 Sakuraba A, Sato T, Naganuma M, Morohoshi Y, Matsuoka K, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T. A pilot open-labeled prospective randomized study between weekly and intensive treatment of granulocyte and monocyte adsorption apheresis for active ulcerative colitis. J Gastroenterol. 2008;43:51-56. [PMID: 18297436 DOI: 10.1007/s00535-007-2129-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
57 Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007;41:874-888. [PMID: 18090155 DOI: 10.1097/mcg.0b013e3180479435] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
58 Nakamura T, Nagahori M, Kanai T, Watanabe M. Current Pharmacologic Therapies and Emerging Alternatives in the Treatment of Ulcerative Colitis. Digestion 2008;77:36-41. [DOI: 10.1159/000111486] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
59 Noguchi A, Watanabe K, Narumi S, Yamagami H, Fujiwara Y, Higuchi K, Oshitani N, Arakawa T. The production of interferon-γ-inducible protein 10 by granulocytes and monocytes is associated with ulcerative colitis disease activity. J Gastroenterol 2007;42:947-56. [DOI: 10.1007/s00535-007-2118-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
60 Matsumoto T, Fukunaga K, Kamikozuru K, Tozawa K, Yokoyama Y, Kusaka T, Onishi K, Miwa H, Nakamura S. Cytapheresis as a Non-Pharmacological Therapy for Inflammatory Bowel Disease. Transfus Med Hemother. 2008;35:18-23. [PMID: 21547106 DOI: 10.1159/000111763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
61 Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007;26:779-794. [PMID: 17767462 DOI: 10.1111/j.1365-2036.2007.03334.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
62 Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin Pediatr Surg 2007;16:164-71. [PMID: 17602971 DOI: 10.1053/j.sempedsurg.2007.04.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
63 Nitta H, Kinoyama M, Teramoto F, Watanabe A, Koga H, Haruma K, Akagi R, Ueda H. Exhaled carbon monoxide concentration is not elevated in patients with inflammatory bowel disease. Clin Exper Med 2007;7:77-81. [DOI: 10.1007/s10238-007-0129-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-33. [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
65 Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn cost-effective? Dig Liver Dis. 2007;39:617-625. [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
66 Takemoto K, Kato J, Kuriyama M, Nawa T, Kurome M, Okada H, Sakaguchi K, Shiratori Y. Predictive factors of efficacy of leukocytapheresis for steroid-resistant ulcerative colitis patients. Digestive and Liver Disease 2007;39:422-9. [DOI: 10.1016/j.dld.2007.01.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
67 Ricart E, Esteve M, Andreu M, Casellas F, Monfort D, Sans M, Oudovenko N, Lafuente R, Panés J. Evaluation of 5 versus 10 granulocyteaphaeresis sessions in steroid-dependent ulcerative colitis: A pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007; 13(15): 2193-2197 [PMID: 17465500 DOI: 10.3748/wjg.v13.i15.2193] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
68 Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci. 2007;52:2725-2731. [PMID: 17404876 DOI: 10.1007/s10620-006-9560-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
69 Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007;52:1427-33. [PMID: 17394078 DOI: 10.1007/s10620-006-9406-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
70 Ljung T, Thomsen OØ, Vatn M, Karlén P, Karlsen LN, Tysk C, Nilsson SU, Kilander A, Gillberg R, Grip O, Lindgren S, Befrits R, Löfberg R. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 2007;42:221-7. [PMID: 17327942 DOI: 10.1080/00365520600979369] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
71 Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007;39:435-7. [PMID: 17379590 DOI: 10.1016/j.dld.2007.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
72 González Carro P, Pérez Roldán F, Roncero García Escribano O, Lafuente R, Legaz Huidobro ML, Amigo Echenagusía A. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease. J Clin Apher 2006;21:249-51. [PMID: 16607627 DOI: 10.1002/jca.20093] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
73 Matsuoka K, Iwao Y, Mori T, Sakuraba A, Yajima T, Hisamatsu T, Okamoto S, Morohoshi Y, Izumiya M, Ichikawa H, Sato T, Inoue N, Ogata H, Hibi T. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007;102:331-7. [PMID: 17156136 DOI: 10.1111/j.1572-0241.2006.00989.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 143] [Article Influence: 10.0] [Reference Citation Analysis]
74 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis: EFFICACY AND ENDOSCOPIC PREDICTION OF CYTAPHERESIS THERAPY IN UC. Alimentary Pharmacology & Therapeutics 2006;24:147-52. [DOI: 10.1111/j.1365-2036.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
75 Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
76 Sands BE, Sandborn WJ, Wolf DC, Katz S, Safdi M, Schwartz DA, Hanauer SB. Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol 2006;40:482-9. [PMID: 16825929 DOI: 10.1097/00004836-200607000-00005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
77 Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci. 2006;51:2031-2038. [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
78 Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis. 2006;12:719-726. [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
79 Watanabe K, Oshitani N, Kamata N, Inagawa M, Yamagami H, Higuchi K, Arakawa T. Efficacy and endoscopic prediction of cytapheresis therapy in patients with refractory and steroid-dependent ulcerative colitis. Aliment Pharmacol Ther Symp Series 2006;2:147-52. [DOI: 10.1111/j.1746-6342.2006.00038.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Sohi S, Cohen RD. Management of refractory ulcerative colitis. Curr Treat Options Gastro 2006;9:234-45. [DOI: 10.1007/s11938-006-0042-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
81 Manoj K, Sigurbjornsson F, Bjarnason I. Leucocyte apheresis for ulcerative colitis: Where do we stand? Digestive and Liver Disease 2006;38:394-6. [DOI: 10.1016/j.dld.2006.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
82 Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Löfberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005;11:7001-6. [PMID: 16437606 DOI: 10.3748/wjg.v11.i44.7001] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
83 Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opinion on Biological Therapy 2006;6:453-66. [DOI: 10.1517/14712598.6.5.453] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
84 Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12 Suppl 1:S15-S21. [PMID: 16378006 DOI: 10.1097/01.mib.0000195387.26892.22] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
85 D'Ovidio V, Aratari A, Viscido A, Marcheggiano A, Papi C, Capurso L, Caprilli R. Mucosal features and granulocyte-monocyte-apheresis in steroid-dependent/refractory ulcerative colitis. Dig Liver Dis. 2006;38:389-394. [PMID: 16569521 DOI: 10.1016/j.dld.2005.12.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
86 Cabriada JL, Doménech E, Gomollón F, González-Carro P, González-Lara V, Hinojosa J, Jiménez-López CE, Nos P, Obrador A, Panès J, Saro C, Varea V, Lafuente R, Guilera M. [Consensus document on the use of granulocytapheresis in patients with inflammatory bowel disease]. Gastroenterol Hepatol 2006;29:85-92. [PMID: 16448611 DOI: 10.1157/13083905] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
87 Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol 2006; 12(4): 520-525 [PMID: 16489663 DOI: 10.3748/wjg.v12.i4.520] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
88 Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher. 2005;20:171-184. [PMID: 15892107 DOI: 10.1002/jca.20046] [Cited by in Crossref: 75] [Cited by in F6Publishing: 79] [Article Influence: 4.4] [Reference Citation Analysis]
89 Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2005;7:485-91. [DOI: 10.1007/s11894-005-0080-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
90 Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004;20:1347-1352. [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 92] [Article Influence: 5.3] [Reference Citation Analysis]
91 Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Rev Gastroenterol Hepatol 2005;2:200-1. [DOI: 10.1038/ncpgasthep0168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]